Protective effects of early interleukin 10 antagonism on injury-induced immune dysfunction

Citation
A. Lyons et al., Protective effects of early interleukin 10 antagonism on injury-induced immune dysfunction, ARCH SURG, 134(12), 1999, pp. 1317-1323
Citations number
26
Categorie Soggetti
Surgery,"Medical Research Diagnosis & Treatment
Journal title
ARCHIVES OF SURGERY
ISSN journal
00040010 → ACNP
Volume
134
Issue
12
Year of publication
1999
Pages
1317 - 1323
Database
ISI
SICI code
0004-0010(199912)134:12<1317:PEOEI1>2.0.ZU;2-1
Abstract
Hypothesis: Interleukin 10 (IL-10) plays a central role in the development of postinjury immune suppression, and early in vivo IL-10 antagonism can be protective. Design: Male A/J mice underwent sham or burn injury and were treated with m onoclonal anti-IL-10 antibody or control antibody at 1 day or 3 days after injury. Their ability to survive polymicrobial sepsis induced by the cecum ligation and puncture (CLP) technique was then tested. The response of sham - and burn-injured mice and burn-injured mice treated with anti-IL-10 to im munization with a T-cell-dependent antigen, trinitrophenyl (TNP)-haptenated ovalbumin (TNP-OVA) was also assessed. Main Outcome Measures: Mortality was monitored for a total of 7 days after CLP to assess the effect of anti-IL-10 therapy on the survival of burn-inju red, immune-compromised mice. Serum antibody isotype formation was measured in sham- and burn-injured mice and burn-injured mice treated with anti-IL- 10 to determine how IL-10 antagonism influenced helper T-cell responses in vivo. In vitro cytokine production by antigen-stimulated spleen cells was a ssessed to study the effect of blocking IL-10 activity at 1 day vs 3 days a fter burn injury. Results: Treating mice with anti-IL-10 at 1 day after injury significantly improved CLP survival, whereas delaying treatment 3 days had no beneficial effect. The analysis of T-cell function in vivo as determined by serum anti body isotype formation indicated that anti-IL-10 treatment at 1 day or 3 da ys after injury increased T helper cell 1-type antibody formation to sham i njury levels by day 10. Moreover, these treatments restored the injury-indu ced reduction of antigen-stimulated IL-2, interferon gamma, and IL-10 produ ction. Conclusions: Interleukin 10 plays an early role in the development of burn injury-induced immune suppression. Its in vivo inhibition at 1 day after in jury may be a useful approach toward preventing the development of injury-i nduced immune dysfunction and may do so by restoring T-cell function and cy tokine production.